Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib treatment and second or third TKI discontinuation in chronic myeloid leukemia
2015-004998-33Phase 2Active
- Sponsor
- Heidelberg University
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Heidelberg University. Primary endpoints: Molecular relapse-free survival at 12 months and Molecular relapse-free survival at 36 months. Started Mar 2016; status: active.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2015-004998-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004998-33.